Posts Tagged ‘Genentech’

Market Rebounds, Call Options Up

It was a good day for for the market and it was a great day for us. The Dow surged 380 points, or 5.8%, and closed at 6,926. If there were another hour of trading today the Dow probably would have hit 7,000. The Nasdaq soared 90 points, or 7%,Read more

More

Start Half Positions In IBM

IBM (IBM, $84.44, down $3.04) continues to plunge and we added the April 100 calls (IBMDT, $0.53, down $0.37) to our Watch List when the call options were at $1.10. They have been cut in half with today’s 3% drop in shares of IBM. The April 95 calls (IBMDS, $1.22,Read more

More

Weekly Wrap for 2/22/09

1. Commentary 2. Gold and Platinum 3. Trading Bank of America 4. 2008/ 2009 Portfolios 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary If 666 is the number of the beast, it must be that of a bear because it roared its ugly head at the market.Read more

More

Weekly Wrap for 2/16/09

1. Commentary 2. Oil and Gold 3. Options Education 4. Credit Spreads 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary The market was under tremendous pressure last week and as the saying goes, pressure bursts pipes. Wall Street took a back seat to Washington as the stimulusRead more

More

Trade Updates: Google Stop Hit/ Akamai Technologies Pops Higher

Google (GOOG, $372.97, down $5.80) is trending lower this morning and the party is over for our February 370 calls (GGDBN, $13.10, down $3.90). We raised the stop yesterday to $15 and the call options were profiled last Monday at $2.30. The trade made 5x your money if you gotRead more

More

Weekly Wrap for 2/8/09

1. Commentary 2. Straddle’s Part 2 (Amazon Keeps on Rolling) 3. Financial Sector (open positions) 4. Akamai Technologies 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary The market had an outstanding week and it has been a minute since I have said that. For all of theRead more

More

Wednesday Morning Update

Here’s a look at what we got going on this morning… The market is in positive territory as BMad is back in the news today. You know, Bernard Madoff, the dude that milked investors for $50 billion in the world’s greatest Ponzi scheme. Bernie told the courts today that heRead more

More

Biotech Grumblings

Genentech (DNA, $82.10, up $0.86) came out with some great news yesterday after the bell and said a late-stage study combining Avastin with Tarceva to treat lung cancer was a huge success. Tarceva is a drug from OSI Pharmaceutical’s (OSIP, $36.39, up $0.79) pipeline and is marketed by Genentech. TheRead more

More

Roche Goes Hostile

Roche threw us a curveball this morning and took its bid for Genentech (DNA, $80.95, down $3.14) directly to the shareholders. The company is now offering about $42 billion, or $86.50 a share for Genentech which is $2.50 less than the offer it made last July. Hogwash. Roche’s attempt toRead more

More

Weekly Wrap 1/25/09

1. Commentary 2. Financials 3. Techs 4. Biotechs 5. Earnings 6. Closing Thoughts ************************************************** 1. Commentary The market continued its slide as the all three major indexes lost ground again last week. There was strength in certain sectors while other sectors continued their volatile ways, especially the financial stocks. TheRead more

More

CFTC Disclosure:

GOVERNMENT REGULATIONS REQUIRE DISCLOSURE OF THE FACT THAT WHILE THESE METHODS MAY HAVE WORKED IN THE PAST, PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE PERFORMANCE. WHILE THERE IS A POTENTIAL FOR PROFITS THERE IS ALSO A RISK OF LOSS. A LOSS INCURRED IN CONNECTION WITH Momentum Options Trading, LLC CAN BE SIGNIFICANT. YOU SHOULD THEREFORE CAREFULLY CONSIDER WHETHER TRADING IS SUITABLE FOR YOU IN LIGHT OF YOUR FINANCIAL CIRCUMSTANCE. THERE IS SUBSTANTIAL RISK IN TRADING. A LOSS INCURRED IN CONNECTION WITH FUTURES TRADING CAN BE SIGNIFICANT. WE MAKE NO CLAIM REGARDING PAST OR FUTURE PERFORMANCE. WE MERELY TRACK EVERY TRADE AND SHOW THE PERFORMANCE OF ALL TRADES THE SYSTEM OR NEWSLETTER PRODUCES. SIMULATED TRADING IS DIFFERENT THAN TRADING REAL MONEY. HYPOTHETICAL RESULTS ARE NOT REAL RESULTS. PLEASE CONTACT YOUR BROKER ABOUT THE RISK OR TRADING STOCKS, OPTIONS OR FUTURES. ALL COMMUNICATIONS ARE OPINIONS NOT ADVICE.

CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.